Last updated: February 13, 2026
What is the current market status of NDC 68094-0802?
NDC 68094-0802 refers to Ruxolitinib (brand name Jakafi), manufactured by Incyte Corporation. It is approved for treating myelofibrosis, polycythemia vera, and certain cases of graft-versus-host disease (GVHD).
The drug has experienced steady market growth driven by expanded indications and increased demand. In 2022, Jakafi's US sales reached approximately $2.2 billion, representing a compound annual growth rate (CAGR) of around 15% since 2018, as reported by IQVIA. Sales are expected to stabilize or modestly grow as newer therapies enter or as indications expand further.
What are the key market drivers and barriers?
Market Drivers
- Expanded indications: Approval for GVHD in 2021 has broadened use beyond hematological conditions.
- Orphan disease status: Facilitates favorable pricing, reimbursement, and market exclusivity.
- Physician familiarity: Established efficacy in primary indications promotes higher prescriber confidence.
- Increased diagnosis rates: Growing awareness leads to higher diagnosis and treatment initiation.
Market Barriers
- Pricing pressures: Payers push back on high-cost therapies, potentially affecting reimbursement.
- Emerging competitors: New JAK inhibitors (e.g., momelotinib, pacritinib) targeting similar conditions might erode market share.
- Generic entry potential: Patent expirations could challenge premium pricing over the long term.
What are recent pricing trends?
In the US, Jakafi's list price averages around $44,000 to $50,000 per month, depending on dosing. Actual net prices are lower after rebates and discounts, usually estimated around $40,000 per month per patient.
Pricing stability has persisted over recent years, with minor adjustments for inflation and market dynamics. The drug remains one of the highest-cost hematologic therapies, supported by its orphan status and exclusive label.
How are price projections expected to evolve?
Short-term (1-3 years)
- Maintained pricing levels due to limited immediate competition and longstanding reimbursement agreements.
- Slight growth possible with the addition of new indications or enhanced dosing efficiency.
Long-term (4-10 years)
- Potential for price declines due to patent expiration or biosimilar development.
- Market penetration of alternative JAK inhibitors could induce price competition.
- Expansion into broader indications may justify premium pricing initially, but eventual generic or biosimilar entry could pressure prices downward.
Compound annual growth estimates
- Sales are projected to grow modestly (around 3-5% CAGR) through 2025 if indications expand coherently with clinical guidelines.
- Once patent exclusivity ends, prices could decrease by 30-50%, aligned with biosimilar market trends observed previously (e.g., infliximab biosimilars).
What is the competitive landscape?
| Competitor |
Indications |
Patent Status |
Market Share (Estimated) |
Price Range |
Notes |
| Incyte Jakafi |
Myelofibrosis, PV, GVHD |
Patent until 2025 |
~70% |
$44,000–$50,000/month |
Market leader |
| Novartis Jakavi |
Myelofibrosis, PV |
Patent until 2032 |
20% |
Similar |
Approved outside US |
| Emerging biosimilars |
Various |
Patent expiries |
Less than 10% initially |
Lower |
Entry expected post-patent expiry |
What are additional policies impacting the market?
- Pricing negotiations: CMS and private payers increasingly negotiate prices for high-cost biologics.
- Market exclusivity: Orphan drug designation secures seven years of exclusivity in the US.
- Patent protections: Patents provide patent extension strategies, delaying biosimilar entry.
- FDA pathways for biosimilars: Reduced hurdles can accelerate biosimilar approvals, affecting future pricing.
Summary of key figures
| Metric |
Data |
| Global sales (2022) |
~$2.2 billion (US only) |
| US list price |
~$44,000–$50,000/month |
| CAGR (2018-2022) |
~15% |
| Patent expiration |
2025 (US) |
| Indications |
Myelofibrosis, PV, GVHD |
Key Takeaways
- Market dominance is maintained primarily through exclusivity and physician familiarity.
- Pricing stability persists but is under pressure from biosimilar development.
- Sales growth depends largely on indication expansion, with long-term risks from patent expiry.
- Pricing and reimbursement strategies will influence long-term revenue potential.
- Emerging competitors and biosimilars pose significant future risks to market share and pricing.
FAQs
1. When does patent expiration usually occur for drugs like Jakafi?
Incyte’s patent for Jakafi is set to expire around 2025 in the US, opening the market for biosimilar competition.
2. How will biosimilars impact Jakafi’s price?
Biosimilars tend to reduce the original biologic's price by 30-50%, affecting revenue and market share.
3. Are there upcoming regulatory or policy changes that could impact pricing?
Yes. Policy shifts towards price negotiation, value-based pricing, and increased biosimilar approval could influence future drug prices.
4. What are the major emerging competitors?
Novartis's Jakavi and other JAK inhibitors like momelotinib and pacritinib are potential competitors, especially as new indications are approved.
5. How does indication expansion affect pricing projections?
Expansion into additional indications can justify higher prices initially but may pressure prices downward once competition materializes or patent protections end.
Sources:
[1] IQVIA, 2023. US Sales Data for Jakafi.
[2] Incyte Corporation. Jakafi prescribing information.
[3] FDA, 2022. Approvals and Patent Data.
[4] Evaluate Pharma, 2022. Hematology Market Trends.
